Cited by 400Nanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryAntibiotics Pharmacokinetics and Efficacy

Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy

Open access
Hussain, Sazid, Joo, Jinmyoung, Kang, Jinyoung, Kim, Byungji, Braun, Gary B., She, Zhi-Gang, Kim, Dokyoung, Mann, Aman P. +6 more·2018·Nature Biomedical Engineering

Abstract

Bacterial resistance to antibiotics has made it necessary to resort to antibiotics that have considerable toxicities. Here, we show that the cyclic 9-amino acid peptide CARGGLKSC (CARG), identified via phage display on Staphylococcus aureus (S. aureus) bacteria and through in vivo screening in mice with S. aureus-induced lung infections, increases the antibacterial activity of CARG-conjugated vancomycin-loaded nanoparticles in S. aureus-infected tissues and reduces the needed overall systemic dose, minimizing side effects. CARG binds specifically to S. aureus bacteria but not Pseudomonas bacteria in vitro, selectively accumulates in S. aureus-infected lungs and skin of mice but not in non-infected tissue and Pseudomonas-infected tissue, and significantly enhances the accumulation of intravenously injected vancomycin-loaded porous silicon nanoparticles bearing the peptide in S. aureus-infected mouse lung tissue. The targeted nanoparticles more effectively suppress staphylococcal infections in vivo relative to equivalent doses of untargeted vancomycin nanoparticles or of free vancomycin. The therapeutic delivery of antibiotic-carrying nanoparticles bearing peptides targeting infected tissue may help combat difficult-to-treat infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41551-017-0187-5

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a 20 day efficacy study, 100% of mice administered peptide-functionalized nanoparticles survived, compared with roughly 40% survival in non-functionalized-nanoparticle and free-vancomycin cohorts.

    “In a 20 day efficacy study, 100% of the mice administered the peptide-functionalized nanoparticles survived, compared with roughly 40% survival in the non-functionalized-nanoparticle and free-vancomycin cohorts.”

    From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [56]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hussain, S., Joo, J., Kang, J., Kim, B., Braun, G. B., She, Z.-G., Kim, D., Mann, A. P., Mölder, T., Teesalu, T., Carnazza, S., Guglielmino, S., Sailor, M. J., & Ruoslahti, E.
Affiliations
  • Sanford Burnham Prebys Medical Discovery Institute (US)
  • Asan Medical Center (KR)
  • University of California San Diego (US)
  • University of Tartu (EE)
  • University of California, Santa Barbara (US)
  • University of Messina (IT)
Corresponding author
Ruoslahti, Erkki
Venue
Nature Biomedical Engineering
Published
2018-01-22
Volume
2
Issue
2
Pages
95-103
ISSN
2157-846X (ISSN-L)
OpenAlex
W2789337312
Cited by
399
References
61
Citations by year
2026: 26 · 2025: 48 · 2024: 56 · 2023: 52 · 2022: 53 · 2021: 53 · 2020: 61 · 2019: 34 · 2018: 15 · 2012: 1
FWCI
13.20
Type
journal article
Language
en
Open access
Locations
  • Nature Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
Funders
  • National Cancer Institute (P30CA030199)
  • National Institute of Allergy and Infectious Diseases (R01AI132413)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
Keywords
antibiotic-loaded nanoparticles, vancomycin, targeted drug delivery, Staphylococcus aureus, phage display, porous silicon nanoparticles, bacterial infection, pulmonary infection, skin infections, antibiotic resistance, Pseudomonas

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review